title: [Retrospective analysis of omalizumab in patients with severe allergic asthma].
abstract: OBJECTIVE
  To assess the efficacy and safety profile of omalizumab treatment. The conditions under which omalizumab was prescribed agreed with those in Xolair® drug information: age > 12 years old, severe uncontrolled asthma, FEV1 < 80%, IgE 30-700 UI/ml and positive test results for perennial allergens.
  
  
  METHODS
  Asthmatic patients treated with omalizumab between January 2010 and July 2011 were evaluated retrospectively. Age, sex, weight, IgE level, concomitant asthma medications, change in FEV1, emergency department visits, hospitalizations, asthma exacerbations and corticosteroids bursts were recorded before and after omalizumab initiation. A 1.5- year period was chosen.
  
  
  RESULTS
  A total of 22 patients were included. The mean weight of subjects was 73 Kg (range, 51-102). Mean IgE was 203 UI/ml (range, 30-992) and mean FEV1 60% (range, 30-93%) at baseline. Adverse events were observed in 4 patients. There were no significant changes in FEV1 values after omalizumab treatment but omalizumab was associated with a reduction in concomitant asthma medications use in 14 patients and improvements in global asthma control in 12.
  
  
  CONCLUSIONS
  In these patients add-on therapy with omalizumab reduced asthma exacerbations and emergency visits or hospitalizations. Only 55% of patients significantly improved global asthma control and no significant changes in FEV1 were observed.
authors.forename: Núria
authors.initials: N
authors.lastname: Padullés Zamora
authors.forename: Dolors
authors.initials: D
authors.lastname: Comas Sugrañes
authors.forename: Nadia
authors.initials: N
authors.lastname: Méndez Cabaleiro
authors.forename: Anna
authors.initials: A
authors.lastname: Figueras Suriol
authors.forename: Ramon
authors.initials: R
authors.lastname: Jodar Masanes
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000485:Allergens / Q000009:adverse effects; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D003521:Cyclopropanes; D004341:Drug Evaluation; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004636:Emergency Service, Hospital / Q000706:statistics & numerical data; D005260:Female; D005541:Forced Expiratory Volume; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use; D012189:Retrospective Studies; D013224:Status Asthmaticus / Q000453:epidemiology / Q000517:prevention & control; D013440:Sulfides; D062606:Tertiary Care Centers / Q000706:statistics & numerical data; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000085:Acetates; D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D000485:Allergens; D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D018680:Cholinergic Antagonists; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D000069444:Omalizumab; D007073:Immunoglobulin E; C093875:montelukast